Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Forxiga, Farxiga, Xigduo XR
Dapagliflozin is an oral anti-diabetic drug belonging to the SGLT2 inhibitor class. It works by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and lowering blood sugar levels. It is primarily used to improve glycemic control in adults with type 2 diabetes mellitus.
For improving glycemic control in adults with type 2 diabetes mellitus, reducing the risk of hospitalization for heart failure, and improving kidney outcomes in patients with chronic kidney disease.
Outcome:
Increased risk of dehydration and hypotension
Mechanism:
Synergistic diuretic effects
Outcome:
Increased risk of hypoglycemia
Mechanism:
Additive hypoglycemic effects
Outcome:
Possible increased risk of gout
Mechanism:
Dapagliflozin can increase serum uric acid levels
Most likely new formulation: Combination therapy with other antidiabetic drugs (2024, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that dapagliflozin will maintain its current regulatory status for the next 5 years.
Antidiabetic, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Glucitol